Chronic aspirin treatment affects collagen deposition in non-infarcted myocardium during remodeling after coronary artery ligation in the rat

Journal of Molecular and Cellular Cardiology
E A KalkmanR G Schoemaker

Abstract

Low-dose aspirin (acetylsalicylic acid; ASA), inhibiting platelet thromboxane production in favor of endothelium formation of prostaglandins, is successfully used as primary or secondary prophylaxis against myocardial infarction. Although prognosis may be improved, effects of long-term ASA treatment on wound healing and cardiac remodeling are not well understood. The aim of the present study was to mimic the clinical situation by inducing myocardial infarction in low-dose ASA (25 mg/kg/day, i.p.) pretreated rats, and to determine effects on plasma eicosanoid levels, cardiac hypertrophy and collagen deposition, and left ventricular function during continued ASA treatment. The effects of this dose were verified to selectively inhibit platelet thromboxane production, and lower plasma levels of thromboxane, but did not affect plasma levels of prostacyclin and prostaglandin E2 during the acute inflammatory stage following myocardial infarction. As measured by heart dry weight/body weight, cardiac hypertrophy was not affected by ASA treatment. However, interstitial fibrosis in the spared myocardium as well as perivascular fibrosis, associated with infarction-induced cardiac remodeling, were affected by ASA treatment. Replacement fibr...Continue Reading

Citations

Nov 24, 2006·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Zhangqiang GuoHeping Guo
Jun 14, 2000·European Journal of Pharmacology·R Van KerckhovenR G Schoemaker
Aug 7, 2002·European Journal of Pharmacology·Roeland Van KerckhovenRegien G Schoemaker
Feb 14, 1998·Journal of the American College of Cardiology·A S Al-KhadraM A Konstam
Dec 18, 2012·Clinical and Experimental Pharmacology & Physiology·Jeanine S dos Santos, Andréa Monte-Alto-Costa
Oct 21, 2000·Journal of Molecular and Cellular Cardiology·J W de JongC Ceconi
Sep 24, 2004·European Journal of Clinical Investigation·P M EllerbroekF E J Coenjaerts
Sep 19, 2006·European Journal of Pharmacology·Mirjam E van AlbadaRegien G Schoemaker
Jul 30, 1999·American Heart Journal·J R Teerlink, B M Massie
Aug 14, 2015·BMC Complementary and Alternative Medicine·Wei LiXianchun Shen
Aug 15, 2006·Journal of the American College of Cardiology·Piet BorgdorffWalter J Paulus
Aug 30, 2003·Molecular Therapy : the Journal of the American Society of Gene Therapy·Hai-Feng DuanLi-Sheng Wang
May 2, 2003·Human & Experimental Toxicology·K DubeyK K Pillai
Feb 3, 2018·British Journal of Pharmacology·Shuaibo Huang, Nikolaos G Frangogiannis
Jan 29, 2008·American Journal of Physiology. Heart and Circulatory Physiology·Hélène BulckaenFrançois Puisieux
Jul 17, 2001·American Journal of Physiology. Heart and Circulatory Physiology·J A DelyaniA E Rudolph
Mar 27, 2007·American Journal of Physiology. Heart and Circulatory Physiology·Eduard I DedkovRobert J Tomanek
Apr 25, 2003·Canadian Journal of Physiology and Pharmacology·Takayuki SaitoAdel Giaid
Jan 5, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Scott P LevickJoseph S Janicki

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiac Remodeling

Cardiac remodeling in response to a myocardial infarction is characterized by progressive ventricular dilatation, cardiac hypertrophy, fibrosis, and deterioration of cardiac performance. Discover the latest research on Cardiac Remodeling here.

Cardiomegaly

Cardiomegaly, known as an enlarged heart, is a multifactorial disease with different pathophysiological mechanisms. Hypertension, pregnancy, exercise-induced and idiopathic causes are some mechanisms of cardiomegaly. Discover the latest research of cardiomegaly here.